

Rowan University

## Rowan Digital Works

---

Stratford Campus Research Day

26th Annual Research Day

---

May 5th, 12:00 AM

### What Motivates Patients to Enroll in a Naloxone Co-Prescribing Program?

Christina Kanagawa  
*Rowan University*

David Aloisio  
*Rowan University*

Eshani Choksi  
*Rowan University*

Manasa Gowda  
*Rowan University*

Tyler Klecha  
*Rowan University*

Follow this and additional works at: [https://rdw.rowan.edu/stratford\\_research\\_day](https://rdw.rowan.edu/stratford_research_day)

See next page for additional authors



Part of the [Behavior and Behavior Mechanisms Commons](#), [Health Services Research Commons](#), [Pharmaceutical Preparations Commons](#), [Substance Abuse and Addiction Commons](#), and the [Therapeutics Commons](#)

Let us know how access to this document benefits you - share your thoughts on our [feedback form](#).

---

Kanagawa, Christina; Aloisio, David; Choksi, Eshani; Gowda, Manasa; Klecha, Tyler; and Defendorf, Charles M., "What Motivates Patients to Enroll in a Naloxone Co-Prescribing Program?" (2022). *Stratford Campus Research Day*. 117.

[https://rdw.rowan.edu/stratford\\_research\\_day/2022/May5/117](https://rdw.rowan.edu/stratford_research_day/2022/May5/117)

This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital Works. It has been accepted for inclusion in Stratford Campus Research Day by an authorized administrator of Rowan Digital Works.

---

**Author(s)**

Christina Kanagawa, David Aloisio, Eshani Choksi, Manasa Gowda, Tyler Klecha, and Charles M. Defendorf



# What Motivates Patients to Enroll in a Naloxone Co-Prescribing Program?

Christina Kanagawa, OMS-II; David Aloisio, OMS-II; Eshani Choksi, OMS-II; Manasa Gowda, OMS-II; Tyler Klecha, OMS-II; Charles Defendorf, DO  
Rowan Medicine Department of Internal Medicine, 42 E Laurel Rd, Stratford, NJ 08084

## Introduction

- Opioid epidemic an on-going public health emergency that claims hundreds of lives every day.<sup>1,2</sup>
- EMS and healthcare professionals use naloxone, an opioid antagonist, to rapidly reverse respiratory and CNS depression from opioid overdose.<sup>3,4</sup>
- Reduction of preventable deaths the goal of co-prescribing naloxone to high-risk patients.


## Methods

- Patients from Rowan Medicine were contacted via phone call to establish:
  - If patients knew what naloxone was
  - Naloxone prescription status:
    - already had naloxone
    - needed an updated prescription
    - would like a first-time prescription
- Patients invited to enroll in research study consisting of two online surveys:
  - Initial survey
    - all participants
    - included “Motivation” question
  - Follow-up survey
    - participants who received an updated or first-time prescription after research group contact

## Results

- Question
  - “Please rank the following motivations for why you chose to accept a consultation in the office to receive a naloxone co-prescription at that time.”
  - Ranking system from 1-7 (1 being most important, 7 being negligible).
- Highest frequency of motivations ranked number 1 by patients
  - “A medical professional recommended it” (10 people)
  - “I want to protect myself” (9 people).

Respondent Rates	
Completed Initial Survey	44
Completed Motivations ?	32
Among the Answered	
Previously Prescribed Naloxone	26
Have Not Received Naloxone	6



## Conclusions

- As the rankings in the figure show, the patients who had been prescribed naloxone by the time the study had started ranked being persuaded by a medical professional as being the most important reason for accepting the naloxone prescription.
- Insufficient data collected during the six weeks of SMRF to draw statistically significant conclusions about what motivates patients to receive naloxone co-prescriptions.
- However, correlations seen in this study are interesting and warrant further investigation.

## Acknowledgements

Thank you to Dr. Charles Defendorf, Dr. Robert Steer, RowanSOM IRB Committee, Rowan Medicine IM Department, and the Summer Medical Research Fellowship grant committee.

## References

1. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. *MMWR Recomm Rep* 2016;65(No. RR-1):1–49. DOI: <http://dx.doi.org/10.15585/mmwr.rr6501e1>
2. Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. *Pharmacoepidemiol Drug Saf.* 2009 Dec;18(12):1166-75. doi: 10.1002/pds.1833.
3. Belz D, Lieb J, Rea T, Eisenberg MS. Naloxone use in a Tiered-Response Emergency Medical Services System. *Prehospital Emergency Care* 2006; 10(4):468-471. DOI: 10.1080/10903120600885134
4. CDC/NCHS, National Vital Statistics Systems, Mortality. CDC WONDER, Atlanta, GA: US Department of Health and Human Services, CDC; 2018. <https://wonder.cdc.gov>.